Prognostic and Diagnostic Added Value of Medical Imaging in Gynecological Cancer (PRODIGYN)

Launched by REGION VÄSTERBOTTEN · May 2, 2023

Keywords

ClinConnect Summary

The PRODIGYN trial is a study that aims to understand how advanced medical imaging can help doctors better diagnose and treat women with cervical, endometrial, and ovarian cancers. Specifically, the researchers want to find out if these imaging techniques can help predict how long patients might live, improve the planning of radiation treatments, and show connections between imaging results and specific markers found in tumor tissue.

Women aged 18 and older who have not yet started treatment for these types of cancer may be eligible to participate. If you join the trial, you will undergo four extra imaging tests in addition to the usual check-ups. These tests will take place at the start of the study and again after three months. The study will follow your health for five years to gather important information. This research is currently looking for participants, so if you fit the criteria, you could help contribute to important findings that may benefit future patients.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Previously untreated primary cervical, endometrial, or strongly suspected epithelial ovarian cancer.
• • Known clinical FIGO stage.
• • \>18 years old.
• • No other known current or previous malignancy within the last 10 years.
• Exclusion Criteria:
• • Imaging findings suggestive of other primary malignancy.
• • Previously included suspected epithelial ovarian cancer, later confirmed to be other diagnosis than epithelial ovarian cancer or "cancer abdominis".
• • MRI incompatible devices or patient unable to undergo MRI.